Dementia

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

DDW Highlights: 2 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More

#Podcasts

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

This week in Drug Discovery (25–29 May) 

News round-up for 25–29 May by Bruno Quinney, Content Team at DDW.  This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments.  The top stories:    UK group steps… Read More

#News

Peptide
#Alzheimer's #Dementia #Peptides

Peptide ‘shuttles’ could transform Alzheimer’s treatment 

Research into the use of peptide ‘shuttles’ has been praised for its potential to overcome barriers in Alzheimer’s and dementia treatment.  Peter Davies, Deputy Director at the Texas A&M Health Institute of Biosciences and Technology, and his colleagues have been awarded a Dementia and Alzheimer’s Initiative (DARI)… Read More

#Editor's Choice #News

#ABPI #Clinical trials #Dementia #GLP-1 #Immune response #Neuroscience #NHS #Obesity #Oncology #Prostate cancer #T cell #Texas A&M University Health Science Center #Tregs #Weight loss

This week in Drug Discovery (23 – 27 March) 

News round-up for 23 – 27 March by Bruno Quinney, Content Team at DDW.  This week, obesity could be treated in other ways than through drugs suppressing appetite. Elsewhere, prostate cancer has been a central theme in cancer research.   The top stories:    Obesity… Read More

#News

Treg cells
#Dementia #Neuroscience #Tregs

Study supports Treg enhancement as dementia treatment

A research study led by Dr Alireza Faridar and Dr Stanley Appel at the Houston Methodist Neurological Institute has demonstrated the involvement of the peripheral immune system in the neuroinflammatory profile of frontotemporal dementia (FTD).  Dr Fred Grossman, Chief Medical Officer at sponsors Coya,… Read More

#Editor's Choice #News

#Alzheimer's #Brain #Breast cancer #Dementia #Genetics #Immunology #Institute of Cancer Research #King's College London #Neuroscience #Parkinson's #Respiratory syncytial virus #Women's health

DDW Highlights: 17 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research on the brain proved a popular theme, unlocking insights into Alzheimer’s, dementia… Read More

#Podcasts

#Alzheimer's #Brain #Breast cancer #Dementia #Genetics #Immunology #Institute of Cancer Research #King's College London #Neuroscience #Parkinson's #Respiratory syncytial virus #Women's health

This week in Drug Discovery (9 – 13 March) 

News round-up for 9 – 13 March February by Bruno Quinney, Content Team at DDW.  This week, research on the brain has proved a popular theme, unlocking insights into Alzheimer’s, dementia and cancer. Elsewhere, a genetic target could provide new routes to breast cancer treatment.  The top stories: … Read More

#News

Microglia in the brain
#Alzheimer's #Dementia #Neuroscience #Texas A&M University Health Science Center

Could extracellular vesicle therapy prevent dementia?

A new research project will test whether extracellular vesicle (EV) therapy can prevent—or even reverse—inflammation in the brain linked to dementia.  Texas A&M Health and the Division of Research created the Dementia & Alzheimer’s Research Initiative (DARI) to prevent, more quickly detect and more effectively treat dementia. … Read More

#Editor's Choice #News

Neurons
#Dementia #Neurodegenerative disorders #Parkinson's #Peptides #University of Bath

Scientists design peptide ‘switch’ to slow Parkinson’s progress

Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of alpha-synuclein, a protein linked to Parkinson’s disease and related dementias.   The team has successfully demonstrated it works in an animal model… Read More

#News #Trending News

#Dementia #GLP-1 #Lupus #Menopause

DDW Highlights: 4 November 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s top story came from women’s health, as Bayer paved the way for… Read More

#Podcasts

Dementia
#Dementia #Neurodegenerative disorders #Phase II trial #Vesper Bio

First oral therapy for frontotemporal degeneration shows promise

Positive topline results from Vesper Bio’s Phase Ib/IIa SORT-IN-2 clinical study evaluating VES001 in asymptomatic carriers with frontotemporal degeneration (FTD) caused by mutations in the progranulin gene (GRN).  Mean progranulin levels increased by more than 95% compared to baseline at the highest dose tested.   As… Read More

#Editor's Choice #News

#Dementia #GLP-1 #Lupus #Menopause #Weight loss

This week in Drug Discovery (27 – 31 October)

News round-up for 27 – 31 October by Bruno Quinney, Content Team at DDW.  Women’s health is top of this week’s agenda, as Bayer paves the way for a new approach to treat hot flashes due to menopause. Elsewhere, an anti-obesity medication has health benefits beyond weight… Read More

#News

Human brain
#Alector #Dementia #Neurodegenerative disorders #Phase III trial

Alector discontinues dementia drug and cuts staff by 49%

Alector has revealed that in a Phase III clinical trial in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) its candidate latozinemab (AL001) did not meet the clinical co-primary endpoint.  Based on the results, the company has announced that the open-label extension portion of… Read More

#Business & Investment #News

#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroscience

What’s next for dementia drug research and development? 

To mark World Alzheimer’s Day on 21 September, Drug Discovery World speaks to biotech companies and investors at the forefront of next-generation dementia drugs.  After years of trudging through something akin to a Slough of Despond, dementia researchers, clinicians and patients have finally been given something to… Read More

#Exclusive Content

Older adult receiving vaccine
#Dementia #GSK #Immunology / Virology & Vaccines #Neuroscience #Shingles

RWD shows shingles vaccine reduces dementia risk

GSK presented six abstracts at the Alzheimer’s Association International Conference (AAIC), including real-world data which shows an association between recombinant zoster vaccine (RZV) and potential reduced risk of dementia.  Tony Wood, Chief Scientific Officer, said: “Building on our expertise in immunology and inflammation, we’re using advanced technology… Read More

#News #Trending News

Degeneration of dopaminergic neuron in Parkinson's disease
#Amyotrophic lateral sclerosis (ALS) #Dementia #Longitude P #MND #Motor neuron disease #Neuroscience

Award transforming drug discovery with AI

The Longitude Prize on ALS is a new £7.5 million ($10.28 million) global challenge prize to incentivise and reward cutting edge AI-based approaches to transform drug discovery for the treatment of amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND). Open for entries from 25 June… Read More

#News